中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
21期
3267-3269
,共3页
结肠肿瘤%抗肿瘤联合化疗方案
結腸腫瘤%抗腫瘤聯閤化療方案
결장종류%항종류연합화료방안
Colonic Neoplasms%Antineoplastic Combined Chemotherapy Protocols
目的：探讨Ⅱ/Ⅲ期结肠癌术后辅助化疗疗效与生存时间。方法选取108例Ⅱ/Ⅲ期结肠癌术后辅助化疗患者作为研究组，选取同期52例仅接受单纯手术治疗的Ⅱ/Ⅲ期结肠癌患者作为对照组，分析两组疗效及随访两组患者生存时间。结果两组患者随访3年，研究组中位无病生存时间18个月，无病生存率为69．44％，复发转移病例26例，占24．07％，死亡7例，占6．48％；对照组中位无病生存时间12个月，无病生存率为46．15％，复发转移病例18例，占34．62％，死亡10例，占19．23％，研究组中位无病生存时间和复发转移均明显优于于对照组（χ2＝8．07、4．74，均P＜0．05）。术后辅助化疗患者毒副反应主要以恶心呕吐、食欲不振、神经毒性及脱发多见，但均比较轻，严重者甚少，大多数患者可耐受。结论Ⅱ/Ⅲ期结肠癌患者术后进行辅助化疗，可降低术后复发转移，延长患者的生存时间。
目的：探討Ⅱ/Ⅲ期結腸癌術後輔助化療療效與生存時間。方法選取108例Ⅱ/Ⅲ期結腸癌術後輔助化療患者作為研究組，選取同期52例僅接受單純手術治療的Ⅱ/Ⅲ期結腸癌患者作為對照組，分析兩組療效及隨訪兩組患者生存時間。結果兩組患者隨訪3年，研究組中位無病生存時間18箇月，無病生存率為69．44％，複髮轉移病例26例，佔24．07％，死亡7例，佔6．48％；對照組中位無病生存時間12箇月，無病生存率為46．15％，複髮轉移病例18例，佔34．62％，死亡10例，佔19．23％，研究組中位無病生存時間和複髮轉移均明顯優于于對照組（χ2＝8．07、4．74，均P＜0．05）。術後輔助化療患者毒副反應主要以噁心嘔吐、食欲不振、神經毒性及脫髮多見，但均比較輕，嚴重者甚少，大多數患者可耐受。結論Ⅱ/Ⅲ期結腸癌患者術後進行輔助化療，可降低術後複髮轉移，延長患者的生存時間。
목적：탐토Ⅱ/Ⅲ기결장암술후보조화료료효여생존시간。방법선취108례Ⅱ/Ⅲ기결장암술후보조화료환자작위연구조，선취동기52례부접수단순수술치료적Ⅱ/Ⅲ기결장암환자작위대조조，분석량조료효급수방량조환자생존시간。결과량조환자수방3년，연구조중위무병생존시간18개월，무병생존솔위69．44％，복발전이병례26례，점24．07％，사망7례，점6．48％；대조조중위무병생존시간12개월，무병생존솔위46．15％，복발전이병례18례，점34．62％，사망10례，점19．23％，연구조중위무병생존시간화복발전이균명현우우우대조조（χ2＝8．07、4．74，균P＜0．05）。술후보조화료환자독부반응주요이악심구토、식욕불진、신경독성급탈발다견，단균비교경，엄중자심소，대다수환자가내수。결론Ⅱ/Ⅲ기결장암환자술후진행보조화료，가강저술후복발전이，연장환자적생존시간。
Objective To study the efficacy of stageⅡ/Ⅲcolon cancer postoperative adjuvant chemotherapy and survival time.Methods 108 stage Ⅱ/Ⅲ colon cancer patients with postoperative adjuvant chemotherapy were selected as the study group,and in the same period 52 stage Ⅱ/Ⅲ colon cancer patients with only simple surgery treatment were selected as the control group.The adjuvant curative effect of the two groups were analyzed and the sur-vival time was followed up.Results The patients of the two groups were followed up for 3 years.The median disease-free survival time of the study group was 18 months,disease-free survival rate was 69.44%,26 cases in recurrence and transfer,accounted for 24.07%,and 7 cases(6.48%) died;The median disease-free survival time of the control group was 12 months and the disease-free survival rate was 46.15%,18 cases in recurrence and transfer, accounted for 34.62%,and 10 cases(19.23%) died.The median disease-free survival,recurrence and transfer rate of the control group were statistically significant better than those of the control group(χ2 =8.07,4.74,all P<0.05).Postoperative adjuvant chemotherapy in patients with adverse reaction was mainly for nausea and vomiting,loss of appetite,pigmentation and hair loss up to see, but were comparatively light, and very little serious most patients could be tolerated.Conclusion The postoperative adjuvant chemotherapy for patients with stageⅡ/Ⅲcolon cancer can reduce postoperative recurrence,metastasis,improve patients'survival time,prolong patient life.
